Lantheus Holdings (LNTH) Share-based Compensation (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Share-based Compensation came in at $15.7 million in Q1 2026, down 33.74% year-on-year from $23.7 million in Q1 2025, and up 137.65% on a QoQ basis from -$41.7 million in Q4 2025.
Lantheus Holdings (LNTH) Share-based Compensation (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Share-based Compensation data on file, last reported at $15.7 million in Q1 2026.
- On a quarterly basis, Share-based Compensation fell 33.74% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $20.8 million, a 149.07% increase from a year earlier, with the FY2025 full-year figure at $26.3 million, up 41706.35% from the prior year.
- Share-based Compensation for Q1 2026 stood at $15.7 million, up from -$41.7 million in the prior quarter.
- Over the last five years, Share-based Compensation for LNTH reached as high as $29.3 million in Q4 2022 and fell as low as -$54.2 million in Q4 2024.
- Historically, Share-based Compensation has averaged $6.5 million across 5 years, with a median of $14.0 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 525.56% in 2024 and fell as far as 255.63% in 2024.
- Year by year, Share-based Compensation stood at $29.3 million in 2022, then sank by 152.05% to -$15.2 million in 2023, then tumbled by 255.63% to -$54.2 million in 2024, then grew by 23.05% to -$41.7 million in 2025, then soared by 137.65% to $15.7 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $15.7 million in Q1 2026, -$41.7 million in Q4 2025, and $24.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 15.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.70 Mn |
| Mar 31, 2026 | 15.70 Mn |
| Dec 31, 2025 | -41.68 Mn |
| Dec 31, 2025 | -41.68 Mn |
| Sep 30, 2025 | 24.50 Mn |
| Sep 30, 2025 | 24.50 Mn |
| Jun 30, 2025 | 22.32 Mn |
| Jun 30, 2025 | 22.32 Mn |
| Mar 31, 2025 | 23.69 Mn |
| Mar 31, 2025 | 23.69 Mn |
| Dec 31, 2024 | -54.17 Mn |
| Dec 31, 2024 | -54.17 Mn |
| Sep 30, 2024 | 20.37 Mn |
| Sep 30, 2024 | 20.37 Mn |
| Jun 30, 2024 | 18.48 Mn |
| Jun 30, 2024 | 18.48 Mn |
| Mar 31, 2024 | 19.42 Mn |
| Mar 31, 2024 | 19.42 Mn |
| Dec 31, 2023 | -15.23 Mn |
| Dec 31, 2023 | -15.23 Mn |